Lilly acquires US co-promotion rights to Livalo from Kowa
This article was originally published in Scrip
Executive Summary
Lilly and Kowa's US subsidiary Kowa Pharmaceuticals America have signed a co-promotion agreement to commercialise Livalo (pitavastatin), a treatment for primary hyperlipidaemia and mixed dyslipidaemia, in the US.